| Aliment Pharmacol Ther 1995 Feb;9(1):33-9
Efficacy of rifaximin in
the treatment of symptomatic diverticular disease of the colon.
A multicentre double-blind placebo-controlled trial.
Papi C, Ciaco A, Koch M, Capurso L.
Department of Digestive Diseases & Nutrition, Ospedale S.
Filippo Neri, Rome, Italy.
BACKGROUND AND AIMS: In a recent open trial we have shown the
efficacy of long term intermittent administration of a poorly
absorbable antibiotic (rifaximin) in obtaining symptomatic relief
in uncomplicated diverticular disease of the colon. The aim
of this double-blind placebo-controlled trial was to test our
previous observations. METHODS: One hundred and sixty-eight
outpatients with symptomatic uncomplicated diverticular disease
were treated with fibre supplementation (glucomannan 2 g/day)
plus rifaximin 400 mg b.d. for 7 days every month (84 patients),
or with glucomannan 2 g/day plus placebo two tablets b.d. for
7 days every month (84 patients). Clinical evaluation was performed
at admission and at three-month intervals for 12 months. RESULTS:
After 12 months, 68.9% of the patients treated with rifaximin
were symptom-free or mildly symptomatic, compared to 39.5% in
the placebo group (P = 0.001). Symptoms such as bloating and
abdominal pain or discomfort were primarily affected by antibiotic
treatment when compared with placebo (P < 0.001). CONCLUSION:
Rifaximin appears to be of some advantage in obtaining symptomatic
relief in diverticular disease of the colon when compared with
fibre supplementation alone.
- Clinical Trial
- Multicenter Study
- Randomized Controlled Trial